Salient Private Client’s Merck MRK Stock Holding History

Salient Private Client’s Portfolio MRK Stock Details MRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-11,618	Closed	-$604K	–	126
2018 Q1	$604K	Sell	11,618 -6,640	-36%	-$359K	0.11%	99
2017 Q4	$980K	Buy	+18,258	New	+$1.01M	0.2%	74

Other funds holding MRK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Salient Private Client's MRK Position: Q2 2018 in Review

Salient Private Client sold out of Merck (MRK) in Q2 2018, closing a stake of 11,618 shares — an estimated $604K sold.

Salient Private Client first reported a position in MRK in Q4 2017 and held it in 2 quarters. The position peaked at $980K in Q4 2017. 2,017 funds tracked by Wall St. Rank hold MRK as of Q2 2018.

Salient Private Client reported no remaining Merck position as of Q2 2018 after selling out during the quarter.
Salient Private Client sold 11,618 Merck shares in Q2 2018, an estimated $604K.
Salient Private Client first reported a position in Merck in Q4 2017 and held it in 2 quarters.
Salient Private Client's Merck position peaked at $980K in Q4 2017.
2,017 funds tracked by Wall St. Rank held Merck as of Q2 2018.

Based on Salient Private Client's 13F filing for Q2 2018, filed 1 Aug 2018.